-
1 day ago | 
oncologynewscentral.com | Youssef Rddad
Bispecific antibodies have reshaped treatment approaches in relapsed multiple myeloma, but delivering them in a community setting comes with logistical and clinical hurdles. Ira Zackon, MD, of New York Oncology Hematology in Albany, discusses how his team in Upstate New York built the infrastructure to safely administer bispecifics, from dedicated clinical teams to hospital partnerships.
-
2 days ago | 
oncologynewscentral.com | Youssef Rddad
Enfortumab vedotin (EV) plus pembrolizumab (EV+P) has quickly moved to the forefront of treatment for advanced urothelial carcinoma. This has raised questions about sequencing, resistance, and next lines of treatment. In an interview with Oncology News Central, Parminder Singh, MD, of the Mayo Clinic in Phoenix, outlined approaches to frontline decision-making and shared insights on options after disease progression.
-
2 days ago | 
oncologynewscentral.com | Youssef Rddad
Switch maintenance with paclitaxel and ramucirumab extended progression-free survival (PFS) compared with continued first-line chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to final results of a phase 3 study. However, the lack of overall survival (OS) benefit and the trial’s design raise questions about whether the findings will affect practice, an expert said.
-
6 days ago | 
oncologynewscentral.com | Neil Osterweil
The theme for the 2025 American Association for Cancer Research (AACR) Annual Meeting, to be held at the McCormick Place Convention Center in Chicago April 25–30, is “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact.”Program Committee Chairs Lillian L.
-
1 week ago | 
oncologynewscentral.com | Youssef Rddad |Manali Bhave |Robert A. Figlin |Stephanie Graff
This transcript has been lightly edited for clarity. Robert A. Figlin, MD, FACP: Hello, this is Bob Figlin, the Cancer Center Director at Cedars-Sinai Cancer and the Steven Spielberg Family Chair in Hematology-Oncology. And I’m absolutely delighted to have back Erika Hamilton, who is the director of breast cancer and gynecologic cancer research at Sarah Cannon in Nashville, and a past chair of the American Society of Clinical Oncology (ASCO) Scientific Breast Committee. Erika, welcome.
-
1 week ago | 
oncologynewscentral.com | Carina Storrs |Youssef Rddad
More work is needed to adequately address sexual and reproductive toxicity in patients receiving treatment for cancer, according to a comment recently published in Lancet Oncology. David J. Benjamin, MD, of the Hoag Family Cancer Institute in Newport Beach, California, and Mark P.
-
1 week ago | 
oncologynewscentral.com | Marcia Frellick
Academic medical centers’ policies and expectations are widely thought to be contributing to an unprecedented wave of oncologist faculty leaving or planning to leave their institutions. In an effort to boost retention by strengthening career and personal satisfaction, the American Society of Clinical Oncology (ASCO) has developed eight new recommendations for academic institutions, which were recently published in the Journal of Clinical Oncology.
-
1 week ago | 
oncologynewscentral.com | Youssef Rddad |Emily Bader
On April 11, the U.S. Food and Drug Administration (FDA) approved the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with previously untreated unresectable or metastatic hepatocellular carcinoma (HCC). The approval follows a similar regulatory move by the European Commission last week. The FDA based its approval on data from the CheckMate 9DW trial, the results of which were presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.
-
1 week ago | 
oncologynewscentral.com | Harsha Vyas |Rebecca Johnson |Carina Storrs |Samyukta Mullangi
An analysis of EHR metadata from 2019 to 2022 found that the number of EHR messages for oncologists grew by 19.0%, with medical oncology hit the hardest. These findings, published in JNCI: Journal of the National Cancer Institute, emphasize the need for health systems to implement approaches that help reduce oncologists’ EHR burden, experts say. “Otherwise, we’re going to lose a really valuable modality for patients and clinicians to communicate in a way they previously wouldn’t have.
-
2 weeks ago | 
oncologynewscentral.com | Ryan Syrek |Youssef Rddad
The U.S. Food and Drug Administration (FDA) granted full approval to larotrectinib (Vitrakvi) for adults and children with NTRK fusion–positive solid tumors that are metastatic, unresectable, or have no other treatment options, drugmaker Bayer announced in an April 10 news release. Regulators based the latest decision on pooled data from the three single-group studies. These included results from the phase 1 LOXO-TRK-14001 trial, the phase 1/2 SCOUT trial, and the phase 2 NAVIGATE trial.